Qnasl Patent Expiration

Qnasl is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 5 US drug patents filed from 2013 to 2019. Out of these, 2 drug patents are active and 3 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Oct 21, 2031. Details of Qnasl's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10188811 Nasal spray device
Oct, 2031

(6 years from now)

Active
US7780038 Dispensing apparatus with dosage counter
Jan, 2027

(2 years from now)

Active
US5776432 Beclomethasone solution aerosol formulations
Jul, 2015

(9 years ago)

Expired
US5683677 Medicinal aerosol formulations
Nov, 2014

(10 years ago)

Expired
US5605674 Medicinal aerosol formulations
Feb, 2014

(10 years ago)

Expired


A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Qnasl's patents.

Given below is the list of recent legal activities going on the following patents of Qnasl.

Activity Date Patent Number
Patent litigations
Payment of Maintenance Fee, 4th Year, Large Entity 20 Jul, 2022 US10188811
Payment of Maintenance Fee, 12th Year, Large Entity 17 Feb, 2022 US7780038
Patent Issue Date Used in PTA Calculation 29 Jan, 2019 US10188811
Recordation of Patent Grant Mailed 29 Jan, 2019 US10188811
Issue Notification Mailed 09 Jan, 2019 US10188811
Application Is Considered Ready for Issue 07 Dec, 2018 US10188811
Dispatch to FDC 07 Dec, 2018 US10188811
Issue Fee Payment Received 05 Dec, 2018 US10188811
Issue Fee Payment Verified 05 Dec, 2018 US10188811
Response to Reasons for Allowance 05 Dec, 2018 US10188811


FDA has granted several exclusivities to Qnasl. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Qnasl, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Qnasl.

Exclusivity Information

Qnasl holds 2 exclusivities. All of its exclusivities have expired in 2017. Details of Qnasl's exclusivity codes and their expiration dates are given below.


Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Mar 23, 2015
New Strength(NS) Dec 17, 2017

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

Several oppositions have been filed on Qnasl's European patents. EP oppositions can significantly impact the timeline for the generic launch of drugs. If an opposition results in the revocation or amendment of a patent, it can shorten the exclusivity period of the original drug. This can lead to an earlier entry of generic versions into the market. To help you estimate the potential early arrival of Qnasl's generic, the next section provides detailed information on ongoing and past EP oppositions related to Qnasl patents.

Qnasl's Oppositions Filed in EPO

Qnasl has faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 22, 2016, by Frkelly. This opposition was filed on patent number EP11779089A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11779089A Jan, 2016 FRKelly Opposition rejected


US patents provide insights into the exclusivity only within the United States, but Qnasl is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qnasl's family patents as well as insights into ongoing legal events on those patents.

Qnasl's Family Patents

Qnasl has patent protection in a total of 32 countries. It's US patent count contributes only to 9.8% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Qnasl.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Qnasl's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Oct 21, 2031 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Qnasl Generics:

There are no approved generic versions for Qnasl as of now.

Alternative Brands for Qnasl

There are several other brand drugs using the same active ingredient (Beclomethasone Dipropionate) as Qnasl. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Norton Waterford
Qvar Redihaler
Teva Branded Pharm
Qvar 40
Qvar 80






About Qnasl

Qnasl is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. Qnasl uses Beclomethasone Dipropionate as an active ingredient. Qnasl was launched by Teva Branded Pharm in 2014.

Approval Date:

Qnasl was approved by FDA for market use on 17 December, 2014.

Active Ingredient:

Qnasl uses Beclomethasone Dipropionate as the active ingredient. Check out other Drugs and Companies using Beclomethasone Dipropionate ingredient

Dosage:

Qnasl is available in aerosol, metered form for nasal use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.08MG/ACTUATION AEROSOL, METERED Prescription NASAL
0.04MG/ACTUATION AEROSOL, METERED Prescription NASAL